Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Part of paid clinical trials in Seattle, Washington.

Sponsor
University of Washington
Study ID
NCT06295965
Status
Recruiting
Apply to this trial

Conditions

  • Clonal Cytopenia of Undetermined Significance
  • Clonal Hematopoiesis
  • Idiopathic Cytopenia of Undetermined Significance
  • Myeloid Neoplasm Post Cytotoxic Therapy
  • Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder
  • Ovarian Carcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Malignant Solid Neoplasm
  • Recurrent Ovarian Carcinoma
  • Recurrent Primary Peritoneal Carcinoma

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Non-Interventional Study — OTHER
    Non-interventional study

Study Details

This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.

Key Dates

Start date
Jan 2, 2024
Status verified
Apr 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2031

Study Design

Enrollment
2,000 participants (estimated)

Arms

  • Arm: Observational
    Patients undergo blood sample collection and complete surveys on study. Patients' medical records are also reviewed.

Primary Outcome Measure

Determine the correlation between baseline TP53m VAF in blood with CH expansion in OC patients [ Time Frame: Through study completion, up to 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Fred Hutch/University of Washington Cancer ConsortiumSeattleWashington98109
Swisher Lab Research Coordinators
[email protected]
206-616-8927
Elizabeth Swisher (PRINCIPAL_INVESTIGATOR)

Find similar trials in Seattle, WA

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Fred Hutch/University of Washington Cancer Consortium· Seattle, WA

Related Studies